(Date:7/24/2008)... CosmetaLife clinical trial results could lea... ,cost-effective treatment for deep lines and wrin... Minn. (PRWEB) July 24, 2008 -- Gel-Del Technolog...e company announced that it has concluded clinical...that company officials say holds potential to be a...
(Date:7/24/2008)... The Palomino Group, a leading commercializat... announced the launch of its new Meeting Support S...tical industry. The company, based in Minneapolis,...ialization consulting services that support biotec... healthcare companies. , ...
(Date:7/24/2008).../PRNewswire-FirstCall/ --, Key Highlights, Misys...ions and is now,raising targets for the next phase...(1) of GBP492m up 6%, bringing Group operating pro... executing on its strategy and entering,into the n...orm for growth., To view the Multimedia News Rele...
(Date:7/23/2008)...ular Entities Drops to Historic Low as Pharma Comp...nerics Companies, LONDON, July 24 /PRNewswire/ --...announced the availability of the newly published ..., an indispensable reference,and business planning...orporate finance, business strategy, marketing pla...
Breaking Medicine News(10 mins):Health News:Clinical Trial Concluded For New Wrinkle Treatment 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 3Health News:The Palomino Group Announces Launch of Meeting Support Services Business Unit 2Health News:The Palomino Group Announces Launch of Meeting Support Services Business Unit 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4Health News:Thomson Reuters Publishes CMR International's 2008 Pharmaceutical R&D Factbook, Now Available for the First Time Online 2(Date:7/22/2008)...(R) Resulted in Significant, Reductions in A1C in ...thm Used, BRIDGE...the "Adjust to,Target in Type 2 Diabetes: Comparis...for Adjustment of Mealtime Insulin Glulisine" stud...tion,s (ADA) medical journal,Diabetes Care. This ...
(Date:7/22/2008)...wswire/ -- Hyperion,Therapeutics, Inc. today annou...ts Phase 1/2 clinical trial to evaluate the safety...PN-100 (formally called GT4P) versus,BUPHENYL(R) (... disorders,(UCD). The company plans to announce to..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...
(Date:7/22/2008)...rsity Medical Center Based on Rosetta Ge...t Differentiates Squamous From Non-Squamous Non-Sm...s-Cell Carcinoma of the Lung With Sensitivi...s is the First CLIA Approved Test Which Leverages ...Accurate Diagnosis of Lung Cancer, REHOVOT, Israe...
(Date:7/22/2008)...ire-FirstCall/ -- NicOx S.A.,(Euronext Paris: COX)...,enrollment of 417 osteoarthritis (OA) patients wi...ology studies in the United States, in line with,p...signed to assess the,blood pressure profile of nap... using the Ambulatory Blood Pressure Monitoring (A...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Rheumatoid arthritis factors equal to cardiovascular factors in risk of severe cardiovascular events 21808 1Rheumatoid arthritis factors equal to cardiovascular factors in risk of severe cardiovascular events 21808 2Nanoparticles aid bone growth 21804 1Nanoparticles aid bone growth 21804 2Courage Center Extends Nomination Deadline for 2008 Phillips Awards to July 3 21800 1Courage Center Extends Nomination Deadline for 2008 Phillips Awards to July 3 21800 2Threatened or invasive 3F Species fates identified 3631 1Threatened or invasive 3F Species fates identified 3631 2...Northfield,Laboratories Inc. (Nasdaq: NFLD) announ...has informed the Company that the report of,the su... with,PolyHeme(R), the Company,s human-hemoglobin ...t be complete until May., About Northfield Laborat...n developing an,oxygen-carrying red blood cell sub...
...tic,benefits of adding Diovan to conventional ther...mes for,Diovan patients , , , BASEL,Switzerlan...dent,Jikei Heart Study, published today in The Lan...ng medication Diovan® to,conventional therapy ...r events and a 40% reduction in stroke. , , The ...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7The GENESIS II* Total Knee System will define the state of knee implants.
Cruciate Retaining, Posterior Stabilized and Constrained Components.
StelKast's Proven knee system is a long term, quality solution based on a clinically proven design. Available in both posterior stabilized and anatomically correct cruciate retaining configurations.
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results.
Medicine Products: